Status:
ACTIVE_NOT_RECRUITING
Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment Evaluation
Lead Sponsor:
Ruijin Hospital
Conditions:
Gastric Cancer (GC)
Eligibility:
All Genders
Brief Summary
This study develops the Surgical Assessment and Healthcare (SAH) Index, a new tool to fairly evaluate gastric cancer surgery outcomes. Gastric cancer is a serious disease that often requires major sur...
Detailed Description
Gastric cancer remains a leading cause of cancer-related mortality worldwide, with significant variation in surgical outcomes across healthcare institutions. Current outcome reporting lacks adequate r...
Eligibility Criteria
Inclusion
- Age: 18 years and older Diagnosis: Histologically confirmed gastric adenocarcinoma Treatment: Underwent surgical resection in 2019 Data availability: Complete clinical, pathological, and molecular marker data Follow-up: Minimum 6 months post-operative follow-up data available
Exclusion
- Histology: Non-adenocarcinoma gastric tumors Surgery type: Emergency surgery or palliative procedures only Data quality: Missing essential clinical, pathological, or molecular data required for SAH Index development Follow-up: Lost to follow-up within 30 days post-surgery
Key Trial Info
Start Date :
September 12 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2025
Estimated Enrollment :
780 Patients enrolled
Trial Details
Trial ID
NCT07180966
Start Date
September 12 2025
End Date
October 1 2025
Last Update
September 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025